Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis

Oncotarget

Volumn 7, Issue 30, 2016, Pages 46848-46861

  Das, Swadesh K ^a,b   Guo, Chunqing ^a   Pradhan, Anjan K ^a   Bhoopathi, Praveen ^a   Talukdar, Sarmistha ^a   Shen, Xue Ning ^a   Emdad, Luni ^a,b   Subler, Mark A ^a   Windle, Jolene J ^a,b   Sarkar, Devanand ^a,b   Wang, Xiang Yang ^a,b   Fisher, Paul B ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Interleukin 17A (IL 17A); Melanoma differentiation associated gene 9 syntenin (mda 9 syntenin); Myeloid derived tumor suppressor cells (MDSC); Syndecan binding protein (SDCBP); Tumor microenvironment

Indexed keywords

INTERLEUKIN 17; RNA; B RAF KINASE; BRAF PROTEIN, MOUSE; IL17A PROTEIN, MOUSE; INTERLEUKIN 6; INTERLEUKIN-6, MOUSE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, MOUSE; SDCBP PROTEIN, MOUSE; SYNTENIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENETICALLY ENGINEERED MOUSE STRAIN; IMMUNE DEFICIENCY; INFLAMMATION; INFLAMMATORY CELL; KNOCKOUT MOUSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA B16; MELANOMA DIFFERENTIATION ASSOCIATED GENE 9; MELANOMA METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SUPPRESSOR CELL; TH17 CELL; TUMOR GENE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE; ANIMAL; CARCINOGENESIS; CELL MOTION; DRUG SCREENING; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; LUNG; LUNG TUMOR; LYMPH NODE; MALE; MELANOCYTE; METABOLISM; MUTATION; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY; SECONDARY; SKIN TUMOR; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-6; LUNG; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOCYTES; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MUTATION; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; SKIN NEOPLASMS; SYNTENINS; TH17 CELLS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84982801667     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10040     Document Type: Article

References (75)

1. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nature reviews Cancer. 2002;2(8):563-72.
2. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature reviews Cancer. 2009;9(4):239-52.
3. Amend SR, Pienta KJ. Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. Oncotarget. 2015;6(12):9669-78. doi: 10.18632/oncotarget.3430.
4. Lin JJ, Jiang HP, Fisher PB. Characterization of a novel melanoma differentiation-associated gene, mda-9, that is down-regulated during terminal cell differentiation. Molecular and Cellular Differentiation. 1996;4(4):317-33.
5. Lin JJ, Jiang H, Fisher PB. Melanoma differentiation associated gene-9, mda-9, is a human gamma interferon responsive gene. Gene. 1998;207(2):105-10.
6. Grootjans JJ, Zimmermann P, Reekmans G, Smets A, Degeest G, Durr J, David G. Syntenin, a PDZ protein that binds syndecan cytoplasmic domains. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(25):13683-8.
7. Boukerche H, Su ZZ, Kang DC, Fisher PB. Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene. 2004;343(1):191-201.
8. Boukerche H, Su ZZ, Prevot C, Sarkar D, Fisher PB. mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(41):15914-9.
9. Boukerche H, Aissaoui H, Prevost C, Hirbec H, Das SK, Su ZZ, Sarkar D, Fisher PB. Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factorkappaB. Oncogene. 2010;29(21):3054-66.
10. Das SK, Bhutia SK, Sokhi UK, Azab B, Su ZZ, Boukerche H, Anwar T, Moen EL, Chatterjee D, Pellecchia M, Sarkar D, Fisher PB. Raf kinase inhibitor RKIP inhibits MDA-9/syntenin-mediated metastasis in melanoma. Cancer research. 2012; 72(23):6217-26.
11. Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, Emdad L, Pellecchia M, Sarkar D, Fisher PB. MDA-9/Syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer research. 2013;73(2):844-54.
12. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, Zimmermann P, David G. Syndecansyntenin-ALIX regulates the biogenesis of exosomes. Nature cell biology. 2012;14(7):677-85.
13. Hurley JH, Odorizzi G. Get on the exosome bus with ALIX. Nature cell biology. 2012;14(7):654-5.
14. Xiao D, Ohlendorf J, Chen Y, Taylor DD, Rai SN, Waigel S, Zacharias W, Hao H, McMasters KM. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. Plos One. 2012;7(10):e46874.
15. Ju R, Zhuang ZW, Zhang JS, Lanahan AA, Kyriakides T, Sessa WC, Simons M. Angiopoietin-2 Secretion by Endothelial Cell Exosomes regulation by the phosphatidylinositol 3-kinase (pi3k)/akt/endothelial nitric oxide synthase (enos) and syndecan-4/syntenin pathways. Journal of Biological Chemistry. 2014;289(1):510-9.
16. Roucourt B, Meeussen S, Bao J, Zimmermann P, David G. Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell research. 2015;25(4):412-28.
17. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Experimental cell research. 2009;315(9):1584-92.
18. Beekman JM, Vervoort SJ, Dekkers F, van Vessem ME, Vendelbosch S, Brugulat-Panes A, van Loosdregt J, Braat AK, Coffer PJ. Syntenin-mediated regulation of Sox4 proteasomal degradation modulates transcriptional output. Oncogene. 2012;31(21):2668-79.
19. Xu NJ, Sun SY, Gibson JR, Henkemeyer M. A dual shaping mechanism for postsynaptic ephrin-B3 as a receptor that sculpts dendrites and synapses. Nature neuroscience. 2011;14(11):1421-U92.
20. Ro YT, Jang BK, Shin CY, Park EU, Kim CG, Yang SI. Akt regulates the expression of MafK, synaptotagmin I, and syntenin-1, which play roles in neuronal function. J Biomed science. 2010;17.
21. McClelland AC, Sheffler-Collins SI, Kayser MS, Dalva MB. Ephrin-B1 and ephrin-B2 mediate EphB-dependent presynaptic development via syntenin-1. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(48):20487-92.
22. Sala-Valdes M, Gordon-Alonso M, Tejera E, Ibanez A, Cabrero JR, Ursa A, Mittelbrunn M, Lozano F, Sanchez-Madrid F, Yanez-Mo M. Association of syntenin-1 with M-RIP polarizes Rac-1 activation during chemotaxis and immune interactions. Journal of cell science. 2012;125(Pt 5):1235-46.
23. Chung JS, Cruz PD, Ariizumi K. Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity. Eur J Immunol. 2011;41(6):1794-9.
24. Chen F, Du Y, Zhang Z, Chen G, Zhang M, Shu HB, Zhai Z, Chen D. Syntenin negatively regulates TRAF6-mediated IL-1R/TLR4 signaling. Cellular signalling. 2008;20(4):666-74.
25. Gimferrer I, Ibanez A, Farnos M, Sarrias MR, Fenutria R, Rosello S, Zimmermann P, David G, Vives J, Serra-Pages C, Lozano F. The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains. Journal of immunology. 2005;175(3):1406-14.
26. Lazic D, Hufbauer M, Zigrino P, Buchholz S, Kazem S, Feltkamp MC, Mauch C, Steger G, Pfister H, Akgul B. Human papillomavirus type 8 E6 oncoprotein inhibits transcription of the PDZ protein syntenin-2. Journal of virology. 2012;86(15):7943-52.
27. Gordon-Alonso M, Rocha-Perugini V, Alvarez S, Moreno-Gonzalo O, Ursa A, Lopez-Martin S, Izquierdo-Useros N, Martinez-Picado J, Munoz-Fernandez MA, Yanez-Mo M, Sanchez-Madrid F. The PDZ-adaptor protein syntenin-1 regulates HIV-1 entry. Molecular biology of the cell. 2012;23(12):2253-63.
28. Tamura K, Ikutani M, Yoshida T, Tanaka-Hayashi A, Yanagibashi T, Inoue R, Nagai Y, Adachi Y, Miyawaki T, Takatsu K, Mori H. Increased production of intestinal immunoglobulins in Syntenin-1-deficient mice. Immunobiology. 2015;220(5):597-604.
29. Hwangbo C, Park J, Lee JH. mda-9/Syntenin protein positively regulates the activation of Akt protein by facilitating integrin-linked kinase adaptor function during adhesion to type I collagen. The Journal of biological chemistry. 2011;286(38):33601-12.
30. Hwangbo C, Kim J, Lee JJ, Lee JH. Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/syntenin. Cancer research. 2010;70(4):1645-55.
31. Dasgupta S, Menezes ME, Das SK, Emdad L, Janjic A, Bhatia S, Mukhopadhyay ND, Shao C, Sarkar D, Fisher PB. Novel role of MDA-9/syntenin in regulating urothelial cell proliferation by modulating EGFR signaling. Clinical cancer research. 2013;19(17):4621-33.
32. Gangemi R, Mirisola V, Barisione G, Fabbi M, Brizzolara A, Lanza F, Mosci C, Salvi S, Gualco M, Truini M, Angelini G, Boccardo S, Cilli M, Airoldi I, Queirolo P, Jager MJ, Daga A, Pfeffer U, Ferrini S. Mda-9/Syntenin is expressed in uveal melanoma and correlates with metastatic progression. Plos One. 2012;7(1), e29989.
33. Oyesanya RA, Bhatia S, Menezes ME, Dumur CI, Singh KP, Bae S, Troyer DA, Wells RB, Sauter ER, Sidransky D, Fisher PB, Semmes OJ, Dasgupta S. MDA-9/Syntenin regulates differentiation and angiogenesis programs in head and neck squamous cell carcinoma. Oncoscience. 2014;1(11):725-37. doi: 10.18632/oncoscience.99.
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
35. Rutkowski MR, Svoronos N, Perales-Puchalt A, Conejo-Garcia JR. The tumor microenvironment: cancerpromoting networks beyond tumor beds. Advances cancer research.2015;128235:235-262.
36. Peske JD, Woods AB, Engelhard VH. Control of CD8 T-Cell Infiltration into Tumors by vasculature and microenvironment. Immunotherapy of cancer. 2015;128:263-307.
37. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature reviews immunology. 2009;9(3):162-74.
38. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of immunology. 2009;182(8):4499-506.
39. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid Derived suppressor cells: Critical cells driving immune suppression in the tumor microenvironment. Immunotherapy of cancer. 2015;128:95-139.
40. Huang B, Pan PY, Li QS, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1(+)CD115(+) immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer research. 2006;66(2):1123-31.
41. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells downregulate L-selectin expression on CD4+ and CD8+ T cells. Journal of immunology. 2009;183(2):937-44.
42. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature reviews cancer. 2005;5(4):263-74.
43. Wang L, Yi TS, Kortylewski M, Pardoll DM, Zeng DF, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. Journal of experimental medicine. 2009;206(7):1457-64.
44. He DG, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, Xu H. IL-17 Promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. Journal of immunology. 2010;184(5):2281-8.
45. Boukerche H, Su ZZ, Emdad L, Baril P, Balme B, Thomas L, Randolph A, Valerie K, Sarkar D, Fisher PB. mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer research. 2005;65(23):10901-11.
46. Rondepierre F, Bouchon B, Bonnet M, Moins N, Chezal JM, D'Incan M, Degoul F. B16 melanoma secretomes and in vitro invasiveness: syntenin as an invasion modulator. Melanoma research. 2010;20(2):77-84.
47. Damsky WE, Rosenbaum LE, Bosenberg M. Decoding melanoma metastasis. Cancers. 2010;3(1):126-63.
48. Qiu HM, Orr FW, Jensen D, Wang HH, McIntosh AR, Hasinoff BB, Nance DM, Pylypas S, Qi K, Song C, Muschel RJ, Al-Mehdi AB. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. American Journal of Pathology. 2003;162(2):403-12.
49. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007;25(18):2546-53.
50. Dankort DPC, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Jr., You MJ, DePinho RA, McMahon M, Bosenberg M. BRafV600E cooperates with Pten silencing to elicit metastatic melanoma. Nat Genet. 2009:Published in final edited form as: Nature Genetics. 2009 May; 41(5): 544-552.
51. Jeon HY, Das SK, Dasgupta S, Emdad L, Sarkar D, Kim SH, Lee SG, Fisher PB. Expression patterns of MDA-9/syntenin during development of the mouse embryo. Journal of molecular histology. 2013;44(2):159-66.
52. Kegelman TP, Das SK, Emdad L, Hu B, Menezes ME, Bhoopathi P, Wang XY, Pellecchia M, Sarkar D, Fisher PB. Targeting tumor invasion: the roles of MDA-9/Syntenin. Expert opinion on therapeutic targets. 2015;19(1):97-112.
53. Das SK, Bhutia SK, Kegelman TP, Peachy L, Oyesanya RA, Dasgupta S, Sokhi UK, Azab B, Dash R, Quinn BA, Kim K, Barral PM, Su ZZ, Boukerche H, Sarkar D, Fisher PB. MDA-9/syntenin: a positive gatekeeper of melanoma metastasis. Frontiers in bioscience: a journal and virtual library. 2012;17:1-15.
54. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99.
55. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature medicine. 2013;19(11):1423-37.
56. Wang XY, Fisher PB. Immunotherapy of Cancer Preface. Immunotherapy of Cancer. Edited by Wang XY and Fisher PB. Advances in Cancer Research. 2015;128:1-375.
57. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell. 2012;21(3):309-22.
58. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Seminars in cancer biology. 2006;16(1):3-15.
59. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nature reviews Cancer. 2013;13(10):739-52.
60. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer immunology, immunotherapy. 2009;58(1):49-59.
61. Guery L and Hugues S. Th17 Cell Plasticity and Functions in Cancer Immunity. BioMed research international. 2015; 2015:314620.
62. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620-7.
63. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. Journal of immunology. 2005;175(9):6177-89.
64. Liu JK, Duan YZ, Cheng XM, Chen X, Xie W, Long HX, Lin ZH, Zhu B. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochemical and biophysical research communications. 2011;407(2):348-54.
65. Du RJ, Zhao H, Yan F, Li H. IL-17(+)Foxp3(+) T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells. J Leukocyte Biol. 2014;96(1):39-48.
66. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nature immunology. 2005;6(12):1182-90.
67. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual review of immunology. 2009;27:485-517.
68. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(21):8137-42.
69. Nishihara M Ogura H, Ueda N, Tsuruoka M, Kitabayashi C, Tsuji F, Aono H, Ishihara K, Huseby E, Betz UA, Murakami M, Hirano T. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. International Immunology 2007 Jun;19(6):695-702 .
70. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. Journal of immunology. 2011;186(6):3462-71.
71. Hayata K, Iwahashi M, Ojima T, Katsuda M, Iida T, Nakamori M, Ueda K, Nakamura M, Miyazawa M, Tsuji T, Yamaue H. Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumorinfiltrating lymphocytes in tumor-bearing mice. Plos One. 2013;8(1):e53131.
72. Lloyd KC. A knockout mouse resource for the biomedical research community. Annals of the New York Academy of Sciences. 2011;1245:24-6.
73. Yu XF, Guo CQ, Yi HF, Qian J, Fisher PB, Subjeck JR, Wang XY. A Multifunctional Chimeric Chaperone Serves as a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity. Cancer research. 2013;73(7):2093-103.
74. Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K, Fisher PB. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer research. 2005;65(19):9056-63.
75. Yi HF, Guo CQ, Yu XF, Zuo DM, Wang XY. Mouse CD11b(+)Gr-1(+) Myeloid Cells Can Promote Th17 Cell Differentiation and Experimental Autoimmune Encephalomyelitis. Journal of immunology. 2012;189(9):4295-304.